{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:54:57Z","timestamp":1791302097094,"version":"4.1.0"},"reference-count":121,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HemaSphere"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>HbSC disease is the second most common type of sickle cell disease (SCD) in populations of African origin. Although it is often grouped together with other types of SCD, particularly sickle cell anemia (HbSS), it has unique pathophysiology and a different spectrum of laboratory and clinical features. Compared to HbSS, hemoglobin levels are higher, HbF is lower at less than 5%, and most vaso\u2010occlusive and vasculopathic complications are less frequent, although retinopathy is more common. Despite these differences, there have been no specific guidelines on the management of HbSC disease. This clinical practice guideline was developed by the European Hematology Association (EHA) in accordance with the EHA Guidelines Methodology Framework to provide consensus\u2010based guidance for the management of children and adults with HbSC disease. A multidisciplinary Guideline Panel was convened by the EHA Guidelines Committee and included hematologists, pediatricians, methodologists, and patient representatives with expertise in SCD and its complications. Panel members were assigned to thematic working groups based on their clinical expertise, and each group was responsible for drafting content and recommendations within their respective domains. Literature searches were conducted using PubMed for relevant studies published in English. A modified Delphi process was used to reach consensus on recommendations, and panel members voted anonymously using an online system. A predefined threshold of \u226570% agreement and &lt;15% disagreement was required for adoption. Statements not reaching consensus were revised and subjected to further rounds of discussion and voting. Thirty\u2010five recommendations were adopted, including guidance on the use of hydroxyurea and therapeutic venesection.<\/jats:p>","DOI":"10.1002\/hem3.70506","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:10:45Z","timestamp":1791299445000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["EHA Guidelines on the management of children and adults with hemoglobin SC disease"],"prefix":"10.1002","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3647-1050","authenticated-orcid":false,"given":"David C.","family":"Rees","sequence":"first","affiliation":[{"name":"School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London London United\u00a0Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentine","family":"Brousse","sequence":"additional","affiliation":[{"name":"Reference Centre for Congenital Red Blood Cell Diseases H\u00f4pital Universitaire Robert Debr\u00e9, APHP Paris France"},{"name":"Universit\u00e9 Paris\u2010Cit\u00e9, INSERM, EFS, BIGR U1134 Paris France"},{"name":"Initiatives IdEx Globule Rouge d'Excellence (InIdex GR\u2010Ex) Universit\u00e9 Paris Cit\u00e9 Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariane","family":"de Montalembert","sequence":"additional","affiliation":[{"name":"Department of General Pediatrics and Pediatric Infectious Diseases, Sickle Cell Center, Necker\u2010Enfants Malades Hospital, Assistance Publique\u2013Ho\u0302pitaux de Paris (AP\u2010HP) Universit\u00e9 Paris\u2010Cit\u00e9; INSERM, EFS, BIGR U1134 Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4426-5743","authenticated-orcid":false,"given":"Bart J.","family":"Biemond","sequence":"additional","affiliation":[{"name":"Department of Hematology Amsterdam University Medical Center, University of Amsterdam  The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7093-777X","authenticated-orcid":false,"given":"Lucia","family":"De Franceschi","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliera Universitaria Integrate, Verona  Italy"},{"name":"Department of Engineering for Innovative Medicine University of Verona Verona Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Oteng\u2010Ntim","sequence":"additional","affiliation":[{"name":"Department of Women and Children's Health School of Lifecourse Sciences, FoLSM, King's College London London United\u00a0Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8638-7944","authenticated-orcid":false,"given":"Pagona","family":"Flevari","sequence":"additional","affiliation":[{"name":"Thalassemia Unit, Laikon General Hospital of Athens Hemoglobinopathies Expertise Center\u2010Member of EuroBloodNet Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8375-6289","authenticated-orcid":false,"given":"Valeria","family":"Pinto","sequence":"additional","affiliation":[{"name":"Hematology and Cellular Therapy IRCCS Azienda Ospedaliera Metropolitana Ospedale Policlinico San Martino Genoa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"James","sequence":"additional","affiliation":[{"name":"Sickle Cell Society London United\u00a0Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5264-8544","authenticated-orcid":false,"given":"Elena","family":"Cela","sequence":"additional","affiliation":[{"name":"Pediatric Hematology Hospital General Universitario Gregorio Mara\u00f1\u00f3n. ERN\u2010EuroBloodNet, Universidad Complutense de Madrid  Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Eber","sequence":"additional","affiliation":[{"name":"M1 Clinic for Children Special Praxis for Paediatric Haematology\/Haemostaseology, Childrens Hospital Technical University  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4056-8026","authenticated-orcid":false,"given":"Rachel","family":"Kesse\u2010Adu","sequence":"additional","affiliation":[{"name":"Guy's and St Thomas NHS Foundation Trust London United\u00a0Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Knight\u2010Madden","sequence":"additional","affiliation":[{"name":"Caribbean Institute for Health Research\u2010Sickle Cell Unit The University of the West Indies Kingston Jamaica"},{"name":"Caribbean Network for Researchers on Sickle Cell Disease and Thalassaemia Kingston Jamaica"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3547-3994","authenticated-orcid":false,"given":"France","family":"Pirenne","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Est Cr\u00e9teil, \u00c9tablissement Fran\u00e7ais du Sang Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Santin","sequence":"additional","affiliation":[{"name":"Assistance Publique\u2010H\u00f4pitaux de Paris, site TENON Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2082-0738","authenticated-orcid":false,"given":"Andreas","family":"Glenth\u00f8j","sequence":"additional","affiliation":[{"name":"Danish Red Blood Cell Center Copenhagen University Hospital\u2013Rigshospitalet Copenhagen Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"issue":"8","key":"e_1_2_16_2_1","doi-asserted-by":"crossref","first-page":"e585","DOI":"10.1016\/S2352-3026(23)00118-7","article-title":"Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000\u22122021: a systematic analysis from the Global Burden of Disease Study 2021","volume":"10","year":"2023","journal-title":"Lancet Haematol"},{"issue":"8","key":"e_1_2_16_3_1","doi-asserted-by":"crossref","first-page":"e633","DOI":"10.1016\/S2352-3026(23)00096-0","article-title":"Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission","volume":"10","author":"Piel FB","year":"2023","journal-title":"Lancet Haematol"},{"issue":"7","key":"e_1_2_16_4_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001484","article-title":"Global burden of sickle cell anaemia in children under five, 2010\u20102050: modelling based on demographics, excess mortality, and interventions","volume":"10","author":"Piel FB","year":"2013","journal-title":"PLoS Med"},{"issue":"10091","key":"e_1_2_16_5_1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0140-6736(17)30193-9","article-title":"Sickle cell disease","volume":"390","author":"Ware RE","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"e_1_2_16_6_1","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/bjh.19523","article-title":"The clinical spectrum of HbSC sickle cell disease\u2010not a benign condition","volume":"205","author":"Nelson M","year":"2024","journal-title":"Br J Haematol"},{"issue":"3","key":"e_1_2_16_7_1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0268-960X(03)00003-1","article-title":"The paradox of hemoglobin SC disease","volume":"17","author":"Nagel RL","year":"2003","journal-title":"Blood Rev"},{"issue":"5","key":"e_1_2_16_8_1","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3324\/haematol.2014.120402","article-title":"The clinical significance of K\u2010Cl cotransport activity in red cells of patients with HbSC disease","volume":"100","author":"Rees DC","year":"2015","journal-title":"Haematologica"},{"issue":"11","key":"e_1_2_16_9_1","doi-asserted-by":"crossref","first-page":"E341","DOI":"10.1002\/ajh.27074","article-title":"Males with sickle cell disease have higher risks of cerebrovascular disease, increased inflammation, and a reduced response to hydroxyurea","volume":"98","author":"Di Mauro M","year":"2023","journal-title":"Am J Hematol"},{"issue":"6","key":"e_1_2_16_10_1","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood-2018-10-880575","article-title":"Decreased median survival of adults with sickle cell disease after adjusting for left truncation bias: a pooled analysis","volume":"133","author":"DeBaun MR","year":"2019","journal-title":"Blood"},{"issue":"18","key":"e_1_2_16_11_1","doi-asserted-by":"crossref","first-page":"E839","DOI":"10.1503\/cmaj.090449","article-title":"AGREE II: advancing guideline development, reporting and evaluation in health care","volume":"182","author":"Brouwers MC","year":"2010","journal-title":"Can Med Assoc J"},{"issue":"6","key":"e_1_2_16_12_1","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/bjh.18794","article-title":"Significant haemoglobinopathies: a guideline for screening and diagnosis: a British Society for Haematology Guideline","volume":"201","author":"Bain BJ","year":"2023","journal-title":"Br J Haematol"},{"issue":"1","key":"e_1_2_16_13_1","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/bjh.19103","article-title":"The Danish national haemoglobinopathy screening programme: report from 16 years of screening in a low\u2010prevalence, non\u2010endemic region","volume":"204","author":"Gravholt EAE","year":"2024","journal-title":"Br J Haematol"},{"issue":"4","key":"e_1_2_16_14_1","first-page":"34","article-title":"Sickle cell anemia in Cuba: prevention and management, 1982\u20102018","volume":"21","author":"Marcheco\u2010Teruel B","year":"2019","journal-title":"MEDICC Rev"},{"issue":"548","key":"e_1_2_16_15_1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3399\/bjgp08X277276","article-title":"Parents' experiences of universal screening for haemoglobin disorders: implications for practice in a new genetics era","volume":"58","author":"Locock L","year":"2008","journal-title":"Br J Gen Pract"},{"issue":"6","key":"e_1_2_16_16_1","article-title":"Genetic carrier screening for cystic fibrosis, Fragile X Syndrome, hemoglobinopathies, and spinal muscular atrophy","volume":"1","author":"Herington E","year":"2021","journal-title":"CADTH Health Technol Rev"},{"issue":"6","key":"e_1_2_16_17_1","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70381","article-title":"EHA recommendations for preconceptual and antenatal screening and prenatal diagnosis for hemoglobinopathies","volume":"10","author":"Montalembert M","year":"2026","journal-title":"HemaSphere"},{"issue":"6","key":"e_1_2_16_18_1","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70381","article-title":"Recommendations for preconceptual and antenatal screening and prenatal diagnosis for hemoglobinopathies","volume":"10","author":"Montalembert M","year":"2026","journal-title":"HemaSphere"},{"issue":"10","key":"e_1_2_16_19_1","first-page":"993","article-title":"Prenatal genetic counseling in cross\u2010cultural medicine: a framework for family physicians","volume":"56","author":"Bhogal AK","year":"2010","journal-title":"Can Fam Physician"},{"issue":"2","key":"e_1_2_16_20_1","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s10897-012-9537-3","article-title":"Who counsels parents of newborns who are carriers of sickle cell anemia or cystic fibrosis?","volume":"22","author":"Moseley KL","year":"2013","journal-title":"J Genet Couns"},{"key":"e_1_2_16_21_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2024.101243","article-title":"Point\u2010of\u2010care diagnostic test accuracy in children and adolescents with sickle cell disease: a systematic review and meta\u2010analysis","volume":"69","author":"Bagnall R","year":"2025","journal-title":"Blood Rev"},{"issue":"4","key":"e_1_2_16_22_1","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/uog.20353","article-title":"Risk of miscarriage following amniocentesis or chorionic villus sampling: systematic review of literature and updated meta\u2010analysis","volume":"54","author":"Salomon LJ","year":"2019","journal-title":"Ultrasound Obstet Gynecol"},{"key":"e_1_2_16_23_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejogrb.2025.114799","article-title":"Non\u2010invasive prenatal testing for the diagnosis of sickle cell disease in high\u2010risk pregnancies: a systematic review and statistical summary of the current literature","volume":"316","author":"Resta C","year":"2026","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"4","key":"e_1_2_16_24_1","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/bjh.14444","article-title":"Knowledge insufficient: the management of haemoglobin SC disease","volume":"176","author":"Pecker LH","year":"2017","journal-title":"Br J Haematol"},{"issue":"2","key":"e_1_2_16_25_1","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/bjh.19580","article-title":"Seeing haemoglobin SC: challenging the misperceptions","volume":"205","author":"Segbefia C","year":"2024","journal-title":"Br J Haematol"},{"issue":"2","key":"e_1_2_16_26_1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s12687-025-00768-5","article-title":"Perceptions of patients and stakeholders on a prenatal sickle cell disease screening and its results among tribal populations of Gujarat: a participatory mixed\u2010method research","volume":"16","author":"Pandya A","year":"2025","journal-title":"J Community Genet"},{"key":"e_1_2_16_27_1","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2147\/JMDH.S90630","article-title":"Sickle cell retinopathy: improving care with a multidisciplinary approach","volume":"10","author":"Menaa F","year":"2017","journal-title":"J Multidiscip Healthc"},{"issue":"13","key":"e_1_2_16_28_1","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1182\/bloodadvances.2022009147","article-title":"Natural history and rate of progression of retinopathy in adult patients with sickle cell disease: an 11\u2010year follow\u2010up study","volume":"7","author":"Brandsen RP","year":"2023","journal-title":"Blood Adv"},{"key":"e_1_2_16_29_1","article-title":"R\u00e9tinopathie dr\u00e9panocytaire: analyse r\u00e9trospective portant sur 730 patients suivis dans un centre de r\u00e9f\u00e9rence","author":"Leveziel N","journal-title":"J Fran\u00e7ais d'Ophtalmol"},{"issue":"5","key":"e_1_2_16_30_1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3324\/haematol.2014.104745","article-title":"Impaired blood rheology plays a role in the chronic disorders associated with sickle cell\u2010hemoglobin C disease","volume":"99","author":"Lemonne N","year":"2014","journal-title":"Haematologica"},{"issue":"5","key":"e_1_2_16_31_1","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.3324\/haematol.2024.286420","article-title":"Clinical and laboratory risk factors for sickle cell retinopathy and maculopathy: a scoping review of the current evidence","volume":"110","author":"Brandsen RP","year":"2025","journal-title":"Haematologica"},{"issue":"1","key":"e_1_2_16_32_1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/IAE.0000000000004658","article-title":"Anti\u2010vascular endothelial growth factor therapy for stages 3 and 4 proliferative sickle cell retinopathy results in improved anatomical and visual outcomes","volume":"46","author":"Lim JI","year":"2026","journal-title":"Retina"},{"issue":"7","key":"e_1_2_16_33_1","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1182\/blood-2015-09-618579","article-title":"Central nervous system complications and management in sickle cell disease","volume":"127","author":"DeBaun MR","year":"2016","journal-title":"Blood"},{"issue":"3","key":"e_1_2_16_34_1","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1067\/mpd.2001.116935","article-title":"Neuropsychologic performance in school\u2010aged children with sickle cell disease: a report from the Cooperative Study of Sickle Cell Disease","volume":"139","author":"Wang W","year":"2001","journal-title":"J Pediatr"},{"issue":"2","key":"e_1_2_16_35_1","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1182\/blood-2014-10-605964","article-title":"Higher\u2010than\u2010expected prevalence of silent cerebral infarcts in children with hemoglobin SC disease","volume":"125","author":"Guilliams KP","year":"2015","journal-title":"Blood"},{"issue":"2","key":"e_1_2_16_36_1","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000519360","article-title":"Unusually high prevalence of stroke and cerebral vasculopathy in hemoglobin SC disease: a retrospective single institution study","volume":"145","author":"Sathi BK","year":"2022","journal-title":"Acta Haematol"},{"issue":"6","key":"e_1_2_16_37_1","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.3324\/haematol.2020.265827","article-title":"Genome wide association study of silent cerebral infarction in sickle cell disease (HbSS and HbSC)","volume":"106","author":"Brewin JN","year":"2021","journal-title":"Haematologica"},{"issue":"1","key":"e_1_2_16_38_1","first-page":"288","article-title":"Cerebrovascular accidents in sickle cell disease: rates and risk factors","volume":"91","author":"Ohene\u2010Frempong K","year":"1998","journal-title":"Blood"},{"issue":"9","key":"e_1_2_16_39_1","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.21476","article-title":"The excess burden of stroke in hospitalized adults with sickle cell disease","volume":"84","author":"Strouse JJ","year":"2009","journal-title":"Am J Hematol"},{"issue":"2","key":"e_1_2_16_40_1","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1136\/adc.2007.125799","article-title":"Transcranial Doppler scanning and the assessment of stroke risk in children with haemoglobin sickle cell disease","volume":"93","author":"Deane CR","year":"2008","journal-title":"Arch Dis Child"},{"issue":"5","key":"e_1_2_16_41_1","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26342","article-title":"Transcranial Doppler in hemoglobin SC disease","volume":"64","author":"Vieira C","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"e_1_2_16_42_1","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1182\/bloodadvances.2019001142","article-title":"American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults","volume":"4","author":"DeBaun MR","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"e_1_2_16_43_1","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/nrneurol.2011.92","article-title":"Do statins improve outcomes after acute ischemic stroke?","volume":"7","author":"Willey JZ","year":"2011","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"e_1_2_16_44_1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/STR.0b013e3181f7d043","article-title":"Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"42","author":"Furie KL","year":"2011","journal-title":"Stroke"},{"issue":"8","key":"e_1_2_16_45_1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.3324\/haematol.2011.055202","article-title":"Hemoglobin sickle cell disease complications: a clinical study of 179 cases","volume":"97","author":"Lionnet F","year":"2012","journal-title":"Haematologica"},{"issue":"7","key":"e_1_2_16_46_1","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.otsr.2009.07.009","article-title":"Treatment of sickle cell disease's hip necrosis by core decompression: a prospective case\u2010control study","volume":"95","author":"Mukisi\u2010Mukaza M","year":"2009","journal-title":"Orthop Traumatol Surg Res"},{"issue":"21","key":"e_1_2_16_47_1","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1056\/NEJM199111213252104","article-title":"Sickle cell disease as a cause of osteonecrosis of the femoral head","volume":"325","author":"Milner PF","year":"1991","journal-title":"N Engl J Med"},{"issue":"15","key":"e_1_2_16_48_1","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1182\/blood-2013-01-480277","article-title":"Does increased red blood cell deformability raise the risk for osteonecrosis in sickle cell anemia?","volume":"121","author":"Lemonne N","year":"2013","journal-title":"Blood"},{"issue":"11","key":"e_1_2_16_49_1","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1007\/s00198-022-06455-2","article-title":"Sickle cell bone disease and response to intravenous bisphosphonates in children","volume":"33","author":"Grimbly C","year":"2022","journal-title":"Osteoporos Int"},{"issue":"1","key":"e_1_2_16_50_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4055\/cios.2016.8.1.1","article-title":"Stem cell therapy for the treatment of hip osteonecrosis: a 30\u2010year review of progress","volume":"8","author":"Hernigou P","year":"2016","journal-title":"Clin Orthop Surg"},{"key":"e_1_2_16_51_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcot.2025.103060","article-title":"Total hip arthroplasty in sickle cell disease: a systematic review and meta\u2010analysis of functional outcomes and complications","volume":"67","author":"Mohabey A","year":"2025","journal-title":"J Clin Orthop Trauma"},{"issue":"2","key":"e_1_2_16_52_1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0002-9343(96)00407-X","article-title":"Natural history of blood pressure in sickle cell disease: risks for stroke and death associated with relative hypertension in sickle cell anemia","volume":"102","author":"Pegelow CH","year":"1997","journal-title":"Am J Med"},{"issue":"4","key":"e_1_2_16_53_1","doi-asserted-by":"crossref","first-page":"e1168","DOI":"10.1542\/peds.2012-2225","article-title":"Weight status of children with sickle cell disease","volume":"131","author":"Chawla A","year":"2013","journal-title":"Pediatrics"},{"issue":"1","key":"e_1_2_16_54_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmjpo-2018-000302","article-title":"High body mass index in children with sickle cell disease: a retrospective single\u2010centre audit","volume":"2","author":"Hall R","year":"2018","journal-title":"BMJ Paediatr Open"},{"issue":"9","key":"e_1_2_16_55_1","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1056\/NEJMoa035477","article-title":"Pulmonary hypertension as a risk factor for death in patients with sickle cell disease","volume":"350","author":"Gladwin MT","year":"2004","journal-title":"N Engl J Med"},{"issue":"5","key":"e_1_2_16_56_1","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/bjh.15238","article-title":"Cardiac manifestations in sickle cell disease varies with patient genotype","volume":"181","author":"Guedeney P","year":"2018","journal-title":"Br J Haematol"},{"issue":"4","key":"e_1_2_16_57_1","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3324\/haematol.2014.114587","article-title":"Elevated hypercoagulability markers in hemoglobin SC disease","volume":"100","author":"Colella MP","year":"2015","journal-title":"Haematologica"},{"issue":"5","key":"e_1_2_16_58_1","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.amjmed.2012.12.016","article-title":"Venous thromboembolism in adults with sickle cell disease: a serious and under\u2010recognized complication","volume":"126","author":"Naik RP","year":"2013","journal-title":"Am J Med"},{"issue":"2","key":"e_1_2_16_59_1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1046\/j.1365-2141.2003.04594.x","article-title":"Causes of death in sickle cell disease: an autopsy study","volume":"123","author":"Manci EA","year":"2003","journal-title":"Br J Haematol"},{"key":"e_1_2_16_60_1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.thromres.2016.03.003","article-title":"Risk factors for venous thromboembolism in adults with hemoglobin SC or S\u03b2+ thalassemia genotypes","volume":"141","author":"Yu TT","year":"2016","journal-title":"Thromb Res"},{"issue":"10","key":"e_1_2_16_61_1","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.3201\/eid2610.202792","article-title":"Coronavirus disease among persons with sickle cell disease, United States, March 20\u2010May 21, 2020","volume":"26","author":"Panepinto JA","year":"2020","journal-title":"Emerging Infect Dis"},{"issue":"8","key":"e_1_2_16_62_1","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s00467-011-1857-2","article-title":"Glomerular hyperfiltration and albuminuria in children with sickle cell anemia","volume":"26","author":"Aygun B","year":"2011","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"e_1_2_16_63_1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2215\/CJN.03940415","article-title":"Kidney disease among patients with sickle cell disease, hemoglobin SS and SC","volume":"11","author":"Drawz P","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"e_1_2_16_64_1","doi-asserted-by":"crossref","first-page":"614","DOI":"10.7326\/0003-4819-115-8-614","article-title":"Chronic renal failure in sickle cell disease: risk factors, clinical course, and mortality","volume":"115","author":"Powars DR","year":"1991","journal-title":"Ann Intern Med"},{"issue":"1","key":"e_1_2_16_65_1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/(SICI)1096-8652(200005)64:1<47::AID-AJH8>3.0.CO;2-1","article-title":"Maximum urine concentrating ability in children with Hb SC disease: effects of hydroxyurea","volume":"64","author":"Iyer R","year":"2000","journal-title":"Am J Hematol"},{"issue":"1","key":"e_1_2_16_66_1","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0022-3476(00)90054-4","article-title":"Gallstones in sickle cell disease: observations from The Jamaican Cohort study","volume":"136","author":"Walker TM","year":"2000","journal-title":"J Pediatr"},{"issue":"3","key":"e_1_2_16_67_1","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ajh.10140","article-title":"Outcome in hemoglobin SC disease: a four\u2010decade observational study of clinical, hematologic, and genetic factors","volume":"70","author":"Powars DR","year":"2002","journal-title":"Am J Hematol"},{"issue":"8","key":"e_1_2_16_68_1","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1182\/blood.V85.8.2238.bloodjournal8582238","article-title":"Functional asplenia in hemoglobin SC disease","volume":"85","author":"Lane P","year":"1995","journal-title":"Blood"},{"issue":"5","key":"e_1_2_16_69_1","doi-asserted-by":"crossref","first-page":"E110","DOI":"10.1002\/ajh.26879","article-title":"Relevance of Howell\u2010Jolly body counts for measuring spleen function in sickle cell disease","volume":"98","author":"Pourdieu C","year":"2023","journal-title":"Am J Hematol"},{"issue":"3","key":"e_1_2_16_70_1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1046\/j.1365-2257.2000.00304.x","article-title":"Palpable splenomegaly in children with haemoglobin SC disease: haematological and clinical manifestations","volume":"22","author":"Zimmerman SA","year":"2000","journal-title":"Clin Lab Haematol"},{"issue":"6","key":"e_1_2_16_71_1","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0022-3476(97)70284-1","article-title":"Acute splenic complications in children with sickle cell\u2010hemoglobin C disease","volume":"130","author":"Aquino VM","year":"1997","journal-title":"J Pediatr"},{"issue":"9","key":"e_1_2_16_72_1","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1046\/j.1464-410X.2002.03022.x","article-title":"Priapism in sickle\u2010cell disease; incidence, risk factors and complications\u2014an international multicentre study","volume":"90","author":"Adeyoju AB","year":"2002","journal-title":"BJU Int"},{"issue":"23","key":"e_1_2_16_73_1","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1182\/blood-2014-09-551887","article-title":"How I treat priapism","volume":"125","author":"Anele UA","year":"2015","journal-title":"Blood"},{"issue":"1","key":"e_1_2_16_74_1","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1182\/hematology.2022000380","article-title":"Epidemiology and treatment of priapism in sickle cell disease","volume":"2022","author":"Idris IM","year":"2022","journal-title":"Hematology"},{"issue":"2","key":"e_1_2_16_75_1","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2013.11.008","article-title":"European Association of Urology guidelines on priapism","volume":"65","author":"Salonia A","year":"2014","journal-title":"Eur Urol"},{"issue":"2","key":"e_1_2_16_76_1","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1182\/bloodadvances.2019001143","article-title":"American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support","volume":"4","author":"Chou ST","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"e_1_2_16_77_1","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1590\/S0100-879X2005000500004","article-title":"Risk factors for alloimmunization by patients with sickle cell disease","volume":"38","author":"Murao M","year":"2005","journal-title":"Braz J Med Biol Res"},{"issue":"17","key":"e_1_2_16_78_1","doi-asserted-by":"crossref","first-page":"4799","DOI":"10.1182\/bloodadvances.2022008647","article-title":"Proinflammatory state promotes red blood cell alloimmunization in pediatric patients with sickle cell disease","volume":"7","author":"Zheng Y","year":"2023","journal-title":"Blood Adv"},{"issue":"25","key":"e_1_2_16_79_1","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1182\/blood-2018-02-785964","article-title":"How I safely transfuse patients with sickle\u2010cell disease and manage delayed hemolytic transfusion reactions","volume":"131","author":"Pirenne F","year":"2018","journal-title":"Blood"},{"issue":"4","key":"e_1_2_16_80_1","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1046\/j.1365-2141.1997.3173132.x","article-title":"Cellular effects of hydroxyurea in Hb SC disease","volume":"98","author":"Steinberg MH","year":"1997","journal-title":"Br J Haematol"},{"issue":"1","key":"e_1_2_16_81_1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood.2024028136","article-title":"A novel mouse model of hemoglobin SC disease reveals mechanisms underlying beneficial effects of hydroxyurea","volume":"146","author":"Setayesh T","year":"2025","journal-title":"Blood"},{"issue":"10","key":"e_1_2_16_82_1","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jama.2014.10517","article-title":"Management of sickle cell disease: summary of the 2014 evidence\u2010based report by expert panel members","volume":"312","author":"Yawn BP","year":"2014","journal-title":"JAMA"},{"issue":"2","key":"e_1_2_16_83_1","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/pbc.24283","article-title":"Hydroxyurea treatment of children with hemoglobin SC disease","volume":"60","author":"Yates AM","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"e_1_2_16_84_1","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/00043426-200106000-00014","article-title":"Hydroxyurea therapy for pediatric patients with hemoglobin SC disease","volume":"23","author":"Miller MK","year":"2001","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"e_1_2_16_85_1","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/ajh.24255","article-title":"Effects of hydroxyurea treatment for patients with hemoglobin SC disease","volume":"91","author":"Luchtman\u2010Jones L","year":"2016","journal-title":"Am J Hematol"},{"issue":"2","key":"e_1_2_16_86_1","article-title":"Hydroxyurea for children and adults with hemoglobin SC disease","volume":"4","author":"Dei\u2010Adomakoh YA","year":"2025","journal-title":"NEJM Evid"},{"issue":"6","key":"e_1_2_16_87_1","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1111\/bjh.19832","article-title":"Baseline characteristics of Ghanaian children and adults enrolled in PIVOT, a randomised clinical trial of hydroxyurea in HbSC disease in sub\u2010Saharan Africa","volume":"205","author":"Segbefia CI","year":"2024","journal-title":"Br J Haematol"},{"issue":"11","key":"e_1_2_16_88_1","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1002\/ajh.70045","article-title":"Iron deficiency in HbSC disease treated with repetitive phlebotomy is associated with fewer sickle cell disease\u2010related complications","volume":"100","author":"Traets MJM","year":"2025","journal-title":"Am J Hematol"},{"issue":"2","key":"e_1_2_16_89_1","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/bjh.70262","article-title":"Iron deficiency is associated with reduced levels of inflammation and haemolysis in patients with HbSS and HbSC and reduced clinical admissions in those with HbSC","volume":"208","author":"Villaboni S","year":"2026","journal-title":"Br J Haematol"},{"issue":"7","key":"e_1_2_16_90_1","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/ajh.24380","article-title":"Iron restriction is an important treatment of hemoglobin SC disease","volume":"91","author":"Lionnet F","year":"2016","journal-title":"Am J Hematol"},{"issue":"7","key":"e_1_2_16_91_1","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1177\/1535370216639737","article-title":"Original research: use of hydroxyurea and phlebotomy in pediatric patients with hemoglobin SC disease","volume":"241","author":"Summarell CCG","year":"2016","journal-title":"Exp Biol Med"},{"issue":"7","key":"e_1_2_16_92_1","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.108","article-title":"Recommendations for diagnosis, treatment, and prevention of iron deficiency and iron deficiency anemia","volume":"8","author":"Iolascon A","year":"2024","journal-title":"HemaSphere"},{"issue":"2","key":"e_1_2_16_93_1","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/bjh.70262","article-title":"Iron deficiency is associated with reduced levels of inflammation and haemolysis in patients with HbSS and HbSC and reduced clinical admissions in those with HbSC","volume":"208","author":"Villaboni S","year":"2026","journal-title":"Br J Haematol"},{"issue":"5","key":"e_1_2_16_94_1","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease","volume":"376","author":"Ataga KI","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"e_1_2_16_95_1","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1056\/NEJMoa1715971","article-title":"A phase 3 trial of l\u2010glutamine in sickle cell disease","volume":"379","author":"Niihara Y","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"e_1_2_16_96_1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/bjh.16504","article-title":"Emerging therapies in sickle cell disease","volume":"190","author":"Nardo\u2010Marino A","year":"2020","journal-title":"Br J Haematol"},{"issue":"7","key":"e_1_2_16_97_1","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1182\/blood.2021014716","article-title":"The oral ferroportin inhibitor vamifeport improves hemodynamics in a mouse model of sickle cell disease","volume":"140","author":"Nyffenegger N","year":"2022","journal-title":"Blood"},{"issue":"1","key":"e_1_2_16_98_1","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/S2352-3026(24)00319-3","article-title":"Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double\u2010blind, randomised, placebo\u2010controlled trial","volume":"12","author":"Idowu M","year":"2025","journal-title":"Lancet Haematol"},{"key":"e_1_2_16_99_1","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2023-182472","article-title":"Iron restricted erythropoiesis under hepcidin mimetic treatment (PN23114) improved disease parameters in a Mouse Model for sickle cell disease","volume":"142","author":"Taranath R","year":"2023","journal-title":"Blood"},{"issue":"5","key":"e_1_2_16_100_1","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1046\/j.1365-2141.2003.04193.x","article-title":"Guidelines for the management of the acute painful crisis in sickle cell disease","volume":"120","author":"Rees DC","year":"2003","journal-title":"Br J Haematol"},{"issue":"1","key":"e_1_2_16_101_1","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1182\/hematology.2024000585","article-title":"Beyond IV push: alternative methods for management of acute pain in SCD","volume":"2024","author":"Azul M","year":"2024","journal-title":"Hematology"},{"issue":"2","key":"e_1_2_16_102_1","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/pbc.22900","article-title":"Acute chest syndrome is associated with history of asthma in hemoglobin SC disease","volume":"57","author":"Poulter EY","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"25","key":"e_1_2_16_103_1","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJM200006223422502","article-title":"Causes and outcomes of the acute chest syndrome in sickle cell disease","volume":"342","author":"Vichinsky EP","year":"2000","journal-title":"N Engl J Med"},{"issue":"10","key":"e_1_2_16_104_1","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.31219","article-title":"Splenic complications in pediatric sickle cell disease: a retrospective cohort review","volume":"71","author":"George A","year":"2024","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"e_1_2_16_105_1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/bjh.12950","article-title":"The spleen and sickle cell disease: the sick(led) spleen","volume":"166","author":"Brousse V","year":"2014","journal-title":"Br J Haematol"},{"issue":"2","key":"e_1_2_16_106_1","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jiph.2019.07.015","article-title":"Dengue in hospitalized children with sickle cell disease: a retrospective cohort study in the French departments of America","volume":"13","author":"Elenga N","year":"2020","journal-title":"J Infect Public Health"},{"issue":"8","key":"e_1_2_16_107_1","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.ebiom.2015.07.002","article-title":"A retrospective analysis of the significance of haemoglobin SS and SC in disease outcome in patients with sickle cell disease and dengue fever","volume":"2","author":"Rankine\u2010Mullings A","year":"2015","journal-title":"EBioMedicine"},{"issue":"22","key":"e_1_2_16_108_1","doi-asserted-by":"crossref","first-page":"5695","DOI":"10.1182\/bloodadvances.2025015947","article-title":"Severe parvovirus B19 infection in patients with sickle cell disease hospitalized in intensive care units","volume":"9","author":"Gendreau S","year":"2025","journal-title":"Blood Adv"},{"issue":"1","key":"e_1_2_16_109_1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.blre.2013.12.002","article-title":"Bone marrow necrosis and fat embolism syndrome in sickle cell disease: increased susceptibility of patients with non\u2010SS genotypes and a possible association with human parvovirus B19 infection","volume":"28","author":"Tsitsikas DA","year":"2014","journal-title":"Blood Rev"},{"issue":"10","key":"e_1_2_16_110_1","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.3324\/haematol.2021.278573","article-title":"Low incidence of COVID\u201019 severe complications in a large cohort of children with sickle cell disease: a protective role for basal interferon\u20101 activation?","volume":"106","author":"Brousse V","year":"2021","journal-title":"Haematologica"},{"issue":"1","key":"e_1_2_16_111_1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/MAO.0000000000004674","article-title":"An analysis of risk factors for sensorineural hearing loss in children with sickle cell disease","volume":"47","author":"Youner ER","year":"2026","journal-title":"Otol Neurotol"},{"issue":"1","key":"e_1_2_16_112_1","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/hematology.2025000744","article-title":"Proactive management to improve outcomes of high\u2010risk pregnancy in people with sickle cell disease","volume":"2025","author":"Obadina MA","year":"2025","journal-title":"Hematology"},{"issue":"5","key":"e_1_2_16_113_1","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1515\/jpm-2023-0378","article-title":"Current obstetric outcomes in Jamaican women with sickle hemoglobinopathy\u2014a balance of risks for aspirin?","volume":"52","author":"Gibson SMP","year":"2024","journal-title":"J Perinat Med"},{"issue":"6","key":"e_1_2_16_114_1","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/bjh.17671","article-title":"Management of sickle cell disease in pregnancy. A British Society for Haematology Guideline","volume":"194","author":"Oteng\u2010Ntim E","year":"2021","journal-title":"Br J Haematol"},{"issue":"1","key":"e_1_2_16_115_1","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood-2018-168","article-title":"Hematopoietic stem cell transplantation in thalassemia and sickle cell disease: report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry: 2000\u22122017","volume":"132","author":"Baronciani D","year":"2018","journal-title":"Blood"},{"issue":"1","key":"e_1_2_16_116_1","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1182\/blood-2024-207944","article-title":"Allogeneic transplantation for sickle cell disease offers high rates of cure with low incidence of severe chronic GVHD in both children and adults: real world data from 2010\u20102021. An analysis of the European Society for Blood and Bone Marrow Transplantation Haemoglobinopathy Registry","volume":"144","author":"Fuente J","year":"2024","journal-title":"Blood"},{"issue":"11","key":"e_1_2_16_117_1","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2016-10-745711","article-title":"Sickle cell disease: an international survey of results of HLA\u2010identical sibling hematopoietic stem cell transplantation","volume":"129","author":"Gluckman E","year":"2017","journal-title":"Blood"},{"key":"e_1_2_16_118_1","doi-asserted-by":"crossref","DOI":"10.1177\/09636897241246351","article-title":"Hematopoietic stem cell transplantation in sickle cell disease: a multidimentional review","volume":"33","author":"Rostami T","year":"2024","journal-title":"Cell Transplant"},{"issue":"24","key":"e_1_2_16_119_1","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1056\/NEJMoa0904971","article-title":"Allogeneic hematopoietic stem\u2010cell transplantation for sickle cell disease","volume":"361","author":"Hsieh MM","year":"2009","journal-title":"N Engl J Med"},{"issue":"3","key":"e_1_2_16_120_1","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70089","article-title":"Selecting patients with sickle cell disease for gene addition or gene editing\u2010based therapeutic approaches: Report on behalf of a joint EHA Specialized Working Group and EBMT Hemoglobinopathies Working Party consensus conference","volume":"9","author":"Franceschi L","year":"2025","journal-title":"HemaSphere"},{"issue":"20","key":"e_1_2_16_121_1","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/blood.2025029964","article-title":"Gene therapy for HbSC disease and other compound heterozygous sickle hemoglobinopathies: a time for inclusion","volume":"146","author":"Wilks A","year":"2025","journal-title":"Blood"},{"issue":"23","key":"e_1_2_16_122_1","doi-asserted-by":"crossref","first-page":"6220","DOI":"10.1182\/bloodadvances.2025016793","article-title":"A mouse model for hemoglobin SC disease recapitulates characteristic human pathologies","volume":"9","author":"Zhai J","year":"2025","journal-title":"Blood Adv"}],"container-title":["HemaSphere"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hem3.70506","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hem3.70506","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hem3.70506","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:10:59Z","timestamp":1791299459000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hem3.70506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":121,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1002\/hem3.70506"],"URL":"https:\/\/doi.org\/10.1002\/hem3.70506","archive":["Portico"],"relation":{},"ISSN":["2572-9241","2572-9241"],"issn-type":[{"value":"2572-9241","type":"print"},{"value":"2572-9241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"2026-05-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70506"}}